Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 1, 26 | Schlosser Michael J | officer: EVP and Chief Clinical Officer | 0 | — | |
Daily · Wilder smoothing
| Sep 1, 26 |
| Schlosser Michael J |
| officer: EVP and Chief Clinical Officer |
| 0 |
| — |
| Sep 1, 26 | Schlosser Michael J | officer: EVP and Chief Clinical Officer | 1,898 @ $82.85 | $157.2K |
| Sep 1, 26 | Schlosser Michael J | officer: EVP and Chief Clinical Officer | 6,290 @ $101.16 | $636.3K |
| Sep 1, 26 | Schlosser Michael J | officer: EVP and Chief Clinical Officer | 4,400 @ $139.06 | $611.9K |
| Sep 1, 26 | Schlosser Michael J | officer: EVP and Chief Clinical Officer | 2,420 @ $145.24 | $351.5K |
| Sep 1, 26 | Schlosser Michael J | officer: EVP and Chief Clinical Officer | 2,370 @ $246.79 | $584.9K |
| Sep 1, 26 | Schlosser Michael J | officer: EVP and Chief Clinical Officer | 4,160 @ $236.61 | $984.3K |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 65.96 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 76.51 | Oscillator | Neutral |
| Williams %R (14) | -12.99 | Oscillator | Sell |
| MACD (12, 26, 9) | 11.21 (Hist 1.06) | Oscillator | Strong Buy |
| Average Directional Index (14) | 29.65 (+DI 30.1 / -DI 13.6) | Trend | Strong Buy |
| EMA 20 | 452.33 | MA | Strong Buy |
| SMA 20 | 449.01 | MA | Strong Buy |
| EMA 50 | 436.12 | MA | Strong Buy |
| SMA 50 | 431.58 | MA | Strong Buy |
| SMA 200 | 444.68 | MA | Strong Buy |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Evaluate the expected performance of HCA (HCA) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
HCA's Q3 results could benefit from higher admissions, occupancy and inpatient revenues, but rising costs and fewer outpatient surgeries cloud the outlook.
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced it will host its eighth annual “Crush the Crisis” national prescription drug take back day. On Saturday, Oct. 24, 2026, HCA Healthcare facilities from across the country will partner with local law enforcement to help patients, families and communities safely and anonymously dispose of unused or expired medications at more than 130 collection sites, helping keep.
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
HCA (HCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 24, 2026 | 7.56 | 7.59 | Beat 0.4% | $20.23B |
| Apr 24, 2026 | 7.12 | 7.15 | Beat 0.4% | $19.11B |
| Jan 27, 2026 | 7.46 | 8.01 | Beat 7.4% | $19.51B |
| Oct 24, 2025 | 5.79 | 6.96 | Beat 20.2% | $19.16B |
| Jul 25, 2025 | 6.29 | 6.84 | Beat 8.7% | $18.61B |
| Apr 25, 2025 | 5.75 | 6.45 | Beat 12.2% | $18.32B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 3 | Sep 11, 2026 | 2026-09-11 17:03:21 | View |
| 4 | Aug 28, 2026 | 2026-08-28 17:00:01 | View |
| 8-K | Jul 29, 2026 | 2026-07-29 16:10:06 | View |
| 10-Q | Jul 28, 2026 | 2026-07-28 16:30:41 | View |
| 8-K | Jul 24, 2026 | 2026-07-24 07:45:42 | View |
| 8-K | Jul 14, 2026 | 2026-07-14 07:40:57 | View |
| 8-K | Jun 18, 2026 | 2026-06-18 09:12:19 | View |
| 4 | May 11, 2026 | 2026-05-11 17:27:42 | View |
| 4 | Apr 30, 2026 | 2026-04-30 19:13:20 | View |
| 4 | Apr 30, 2026 | 2026-04-30 19:06:13 | View |
Proxy statement (DEF 14A) disclosures
| Executive | Salary | Stock | Total |
|---|---|---|---|
| Samuel N. Hazen Chief Executive Officer | $1.58M | $8.47M | $26.46M |
| Jon M. Foster Executive Vice President and Chief Operating Officer | $1.04M | $1.90M | $10.99M |
| Michael A. Marks Executive Vice President and Chief Financial Officer | $982.5K | $1.78M | $10.36M |
| Michael R. McAlevey Executive Vice President – Chief Legal and Administrative Officer | $1.01M | $1.27M | $5.71M |
| Michael S. Cuffe, M.D. Executive Vice President and Chief Clinical Officer | $974.8K | $1.27M | $5.70M |
TTM vs. 5-year historical average (annual ratios)
| Metric | HCA | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 15.8x | 13.6x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 16.0x | EPS est. 29.50 | In line |
| Price / Book | -16.0x | -40.9x | Discount |
| Price / Sales | 1.3x | 1.2x | In line |
| EV / EBITDA | 9.5x | 8.9x | In line |
| Return on equity | -112.9% | — | Weak |
| Gross margin | 28.4% | 39.7% | Below hist. |
| Debt / Equity | -7.42 | -20.78 | Conservative |
| Piotroski / Altman Z | 7/9 | Z 2.67 | Grey zone |
Discounted cash flow model
Current price $472.36
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 12, 26 | TD Cowen | maintain | Buy | Buy |
| Oct 7, 26 | RBC Capital | maintain | Outperform | Outperform |
| Sep 18, 26 | Leerink Partners | maintain | Outperform | Outperform |
| Sep 8, 26 | RBC Capital | maintain | Outperform | Outperform |
| Aug 20, 26 | JP Morgan | maintain | Neutral | Neutral |
| Aug 3, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Jul 28, 26 | Goldman Sachs | maintain | Buy | Buy |
| Jul 28, 26 | Mizuho | maintain | Outperform | Outperform |
| Jul 27, 26 | Keybanc | maintain | Overweight | Overweight |